French data show 75% of AstraZeneca jabs unused

vaccine
Credit: Pixabay/CC0 Public Domain

The French government was under pressure on Tuesday to accelerate its vaccination programme after new figures showed that three in four jabs delivered by AstraZeneca had gone unused.

An official in the told reporters on Tuesday that out of 600,000 doses delivered to health centres since early February, only a quarter of them had been administered.

"There is an issue with uptake... because we can see that around 75 percent of stocks have not been injected," the official told journalists at a briefing, asking not to be named.

On Monday evening, France moved to widen the population eligible for the Anglo-Swedish firm's jab, which up until now has been only offered to medical and care personnel below 65 years old and people in high-risk categories from 50-64.

Previous guidance had prevented the vaccination being offered to anyone aged over 65, but Health Minister Olivier Veran reversed this stance following new data showing the jab's efficacy.

"Now that we have good news about AstraZeneca, we absolutely need to find a place for this in our ," the health ministry official said.

France's top authority, HAS, also changed its advice on Tuesday, saying that pharmacy workers should be able to administer all three authorised vaccinations against COVID-19.

It had previously recommended they only have access to the AstraZeneca jab, but not shots by Pfizer/BioNtech and Moderna, which require storage in ultra-low freezers.

France's vaccine strategy has been criticised for being slow and overly bureaucratic, with the country lagging far behind trail-blazing neighbour Britain, as well as Germany and Italy, measured by the number of doses administered.


Explore further

Follow the latest news on the coronavirus (COVID-19) outbreak

© 2021 AFP

Citation: French data show 75% of AstraZeneca jabs unused (2021, March 2) retrieved 19 April 2021 from https://medicalxpress.com/news/2021-03-french-astrazeneca-jabs-unused.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
2 shares

Feedback to editors

User comments